ICM Clinical Trials

Staff

PARTNER/PARTNERING

PI: Jean Abraham Trial for women with early triple negative (TNBC) and BRCA mutation positive (BRCA+BC) breast cancer. Neoadjuvant chemotherapy is commonly used to shrink tumours prior to surgical intervention. Improving the effectiveness of pre-operative, neoadjuvant chemotherapy for patients with TNBC and/or BRCA+BC is important since the amount of residual tumour at surgery is closely associated with clinical outcome. Our PARTNERtrial is investigating the use of a new cancer drug, Olaparib, in the pre-operative, neoadjuvant setting. Olaparib blocks the activity of an enzyme called poly ADP ribose polymerase (PARP) that repairs DNA. Cancer cells with mutations in BRCA1/2 are thought to have a unique vulnerability to Olaparib since they rely on PARP to repair their DNA and enable them to continue dividing. The PARTNER trial is testing if Olaparib is safe to add to platinum-based, pre-operative, neoadjuvant chemotherapy for TNBC and/or BRCA+BC and whether it improves the effectiveness of platinum chemotherapy alone. The PARTNERING component of the trial is also seeking to establish if the addition of further novel drugs (Olaparib, Wee1 inhibitor and PDL1 inhibitor) improves the response at surgery in those patients who are poor responders to the initial treatment within the PARTNER trial.

WIRE

PI: Grant Stewart WIndow-of-opportunity clinical trial platform for evaluation of novel treatment strategies in REnal cell cancer. Window of opportunity for patients with kidney cancer due to the 1 months waiting period from diagnosis to surgery (standard of care). Phase I: combinatorial therpay in clear cell Renal Carcinoma (ccRCC) (VEGF, DDRI, IO,...) Biological rational for drug combinations due to RCC biology and the suggested role of DDR inhibitors. • Olaparib & Cediranib • PARPi & IO Aim: Proof of mechanism defined by biological evidence of agent(s) engaging the predicted cellular pathway, by meeting 2 of the following criteria. • reduced tumour permeability • reduced tumour proliferation • increased apoptosis • inhibition of relevant pathway defined for each treatment arm

ATRIUM

PI: Duncan Jodrell Use of Gemcitabine as a sensitizer for ATR inhibition in the treatment of selected patients with pancreatic cancer. Using model based, dual agent clinical trial design. This trial should overcome the current “challenges” of combining cytotoxic agents with DDR inhibitors. Will increase scientific understanding of the interplay between chemotherapy, DDR modulating agents and DDR/DDR combos, providing both AZD6738 (ATRi) and broader portfolio impact.